Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00GOV
|
|||
| Former ID |
DNCL003443
|
|||
| Drug Name |
Nivolumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Approved | [1], [2] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Approved | [3] | ||
| Esophageal cancer [ICD-11: 2B70; ICD-9: 150] | Phase 3 | [4] | ||
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-10: C16] | Phase 3 | [4] | ||
| Malignant pleural mesothelioma [ICD-11: 2C26.0; ICD-9: 163] | Phase 3 | [4] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 3 | [4] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 3 | [4] | ||
| Small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162.9] | Phase 3 | [4] | ||
| Central nervous system lymphoma [ICD-11: 2B33.5; ICD-10: C69] | Phase 2 | [4] | ||
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2 | [4] | ||
| Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 2 | [4] | ||
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [4] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [4] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 1/2 | [4] | ||
| Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 1/2 | [4] | ||
| Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.7; ICD-9: 205.1] | Phase 1 | [4] | ||
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Application submitted | [4] | ||
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | Modulator | [5] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7335). | |||
| REF 2 | Nivolumab, a Novel Anti D-1 Monoclonal Antibody for the Treatment of Solid and Hematologic Malignancies (Personalized Medicine in Oncology). Emma Thornton. Anti-PD-1 Therapy. June 2014 | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.